A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

NCT04212013 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Rituximab
OTHER: Placebo

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]